Prospective multicenter clinical study of Luqi Decoction in the treatment of chronic heart failure (stage C)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003716

Enrollment

Unknown

Registered

2020-08-25

Start date

2021-01-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

control group :Basic treatment + placebo

experimental group:Basic treatment + Luqi prescription

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) According to the diagnostic criteria of stage C of heart failure; (2) The age is over 18 years old, male and female are not limited; (3) The clinical observation data were collected completely; (4) The subjects agreed to test the relevant clinical indicators.

Exclusion criteria

Exclusion criteria: (1) Patients with definite multi system infection, tumor, connective tissue disease, autoimmune disease, recent operation or trauma; (2) Moderate to severe dementia or mental illness can not cooperate with follow-up investigation; (3) Pregnant and lactating women; (4) The patients died in the acute phase.

Design outcomes

Primary

Measure	Time frame
6-minute walking distance;	—

Secondary

Measure	Time frame
Mortality, readmission rate;BNP;NYHA cardiac function classification;Minnesota quality of life scale;Cardiac MRI;Improvement of TCM Syndromes;Metabonomics and proteomics;Colour Sonography;	—

Countries

China

Contacts

Public ContactZhou Hua

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

zhouhuam@hotmail.com+86 13061717598

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026